HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Dealmaker Saunders Includes Wellness Space In Acquisition Group’s Investment Targets

Executive Summary

Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.

You may also be interested in...

AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan

AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.

Allergan's Restasis Defense Falters As PTAB Dismisses Tribal Immunity Ploy

The damage inflicted by Mylan and other manufacturers looking to sell Restasis generics already has been felt by Allergan, but the PTAB dealt the dry eye drug's patent defense another blow by rejecting the Mohawk Tribe's plea to have an inter partes review thrown out.

Teva Gets What It Wants – Allergan Generics, Not Mylan

Teva’s $40.5 billion acquisition of Allergan Generics will solidify Teva as the world’s leading generics company with $26 billion in combined revenues and 320 ANDAs pending at FDA.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts